5 assets in Hoyeraal-Hreidarsson Syndrome

Therapeutic assets addressing Hoyeraal-Hreidarsson Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Alemtuzumab Hoyeraal-Hreidarsson Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Cyclophosphamide Hoyeraal-Hreidarsson Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Fludarabine Hoyeraal-Hreidarsson Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Melphalan Hoyeraal-Hreidarsson Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Tacrolimus Hoyeraal-Hreidarsson Syndrome	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)